Zydus Lifesciences Reports Growth in Q4 FY26 Financial Results

Zydus Lifesciences has reported its financial performance for the fourth quarter (Q4) of the 2025-26 financial year (FY26), highlighting a period of operational expansion and strategic growth. The company announced a consolidated net profit of ₹1,272.5 crore, marking an 8.7 per cent year-on-year increase. Revenue from operations for the same period rose 16 per cent to reach ₹7,587 crore.

Strategic Performance and Market Outlook

The company’s growth trajectory in the final quarter was supported by strong performances across its diverse portfolio. For the full fiscal year, Zydus Lifesciences recorded an 11 per cent increase in net profit, while revenue from operations grew by 17 per cent.

Sharvil Patel, managing director of Zydus Lifesciences, noted the company’s ability to meet its commitments regarding both revenue and profitability. According to Patel, the company’s near-term strategy focuses on maintaining consistent quality standards, integrating recent acquisitions, and capturing synergies. The firm maintains a strong balance sheet, which leadership suggests provides the necessary flexibility for continued investment and business expansion.

Segmental Highlights

The company’s various business units demonstrated mixed but overall positive results during the quarter:

• India Formulations: This segment saw a 14 per cent year-on-year revenue increase to ₹1,752.8 crore, contributing 24 per cent to the consolidated total. Growth was particularly strong in chronic therapies, including cardiology, respiratory, and dermatology.
• Biosimilars and Specialty: Zydus expanded its domestic footprint with the launch of Tishtha (a biosimilar of Nivolumab) and Anyra (a biosimilar of Aflibercept). The company also entered the diabetes and obesity market with semaglutide products, supported by co-marketing partnerships with Lupin and Torrent Pharmaceuticals.
• North America: The formulations business in this region reported revenue of ₹3,074 crore, reflecting a 6 per cent year-on-year decline. Despite the dip, the company continued its regulatory progress, filing three Abbreviated New Drug Applications (ANDAs), receiving nine approvals, and launching six new products. The firm also introduced Zycubo for the treatment of Menkes disease.
• International Markets and Wellness: The international formulations business grew 45 per cent year-on-year to ₹804 crore. The consumer wellness business saw a significant rise of 61 per cent to ₹1,463.3 crore, driven by performance in skin and hair care brands. The MedTech division contributed ₹327.5 crore to the quarter’s revenue.

Key Takeaways

• Financial Growth: Consolidated net profit reached ₹1,272.5 crore, reflecting an 8.7 per cent year-on-year rise.
• Portfolio Expansion: The company continues to prioritize its biosimilars and chronic therapy portfolios, including new launches in the obesity and rare disease segments.
• Operational Focus: Management is prioritizing the integration of recent acquisitions and the realization of synergies to drive future growth.
• Market Reaction: Following the announcement, Zydus Lifesciences shares rose 2.8 per cent, closing at ₹1,018.9 on the BSE.

Looking Ahead

As Zydus Lifesciences moves into the new fiscal year, its focus remains on leveraging its current pipeline to drive visibility and growth. By balancing its established business units with targeted investments in niche therapies and biosimilars, the company aims to maintain its competitive position in both the Indian and global pharmaceutical markets. Investors and stakeholders will likely monitor the integration of recent acquisitions and the performance of new product launches as key indicators of sustained momentum.